Koj puas paub ACE-031?
I. ACE-031 yog dab tsi?
ACE-031 yog ib qho recombinant fusion protein (ActRIIB-Fc) tsim los ntawm fusion ntawm extracellular domain ntawm activin receptor IIB (ActRIIB) thiab IgG1-Fc fragment. Nws ua raws li "decoy receptor" rau myostatin thiab TGF- superfamily ligands, thaiv lawv cov teeb liab hloov, txo cov leeg kev loj hlob inhibition, thiab txhawb cov leeg loj hlob thiab kho.
II. Khoom Parameters
Lub Npe: Activin Receptor IIB-Fc Fusion Protein (ACE-031)
Lub npe: Myostatin inhibitory peptide 7
Molecular Formula: C₁₃₃H₂₂₇N₄₃O₃₃; Molecular Luj: 2956.5
Cov tsos mob: Dawb sterile lyophilized hmoov
Purity: Ntau dua lossis sib npaug li 99% (HPLC)
Specifications: 1mg / vial, 5mg / vial
Cia: Cov hmoov qhuav tuaj yeem khaws cia rau 3 xyoos ntawm -20 degree, 2 xyoos ntawm 4 degree; Tom qab hloov kho, nws tuaj yeem khaws cia rau 1 lub hlis ntawm -20 degree, 6 lub hlis ntawm -80 degree
Ib nrab-lub neej: Ntev ntev (kwv yees li ob peb hnub), haum rau kev txhaj tshuaj txhua lub lim tiam
III. Product Functions thiab Core Advantages
Lub luag haujlwm tseem ceeb ntawm ACE-031 yog raws li "decoy receptor," ncig hauv lub cev thiab khi rau cov proteins xws li myostatin. Myostatin yog ib txwm tshwm sim "brake" protein nyob rau hauv tib neeg lub cev uas txwv tsis pub cov leeg nqaij ntau dhau. Los ntawm neutralizing cov teeb meem inhibitory, ACE-031 tuaj yeem tshem tawm cov kev txwv ntawm cov leeg nqaij, yog li txhawb cov leeg nqaij hypertrophy thiab txhim kho lub zog.
Nws lub ntsiab zoo yog:
Kev loj hlob zoo ntawm cov leeg nqaij: Cov ntaub ntawv kho mob qhia tau tias ib koob tshuaj tuaj yeem ua rau lub cev hnyav tag nrho thiab cov leeg pob txha hauv lub sijhawm luv.
Ntau yam txiaj ntsig: Ntxiv nrog rau kev loj hlob ntawm cov leeg, cov kev tshawb fawb kuj tau pom tias nws yuav muaj txiaj ntsig zoo rau kev txhim kho pob txha lub zog thiab cov roj metabolism.
Ntev- cov nyhuv kav ntev: Ib nrab- lub neej ntawm 10-15 hnub txhais tau hais tias tsis tas yuav tsum tau noj ntau zaus.
IV. Clinical Value thiab Development History
Txoj kev loj hlob ntawm ACE-031 tau tsom mus rau kev kho mob ntawm cov leeg nqaij atrophy, tshwj xeeb yog Duchenne muscular dystrophy (DMD), thiab tau txais Orphan Drug Designation thiab Fast Track designation los ntawm US FDA.
Hauv Phase I soj ntsuam hauv cov poj niam noj qab haus huv postmenopausal, ib qho kev txhaj tshuaj ntawm ACE-031 ntawm ib koob ntawm 3 mg / kg pom cov leeg nqaij loj hlob tom qab 29 hnub: qhov nruab nrab nce ntawm 3.3% hauv tag nrho cov nqaij ntshiv thiab qhov nruab nrab nce ntawm 5.1% hauv cov leeg nqaij.
Txawm li cas los xij, hauv Phase II kev soj ntsuam hauv cov neeg mob DMD, kev txhim kho ntawm cov tshuaj tau raug txiav tawm vim qhov kev xav tsis zoo xws li ntshav ntswg thiab telangiectasia (cov hlab ntsha me me liab tshwm rau ntawm daim tawv nqaij). Txawm hais tias qhov kev sim ua tsis tiav, nws muab cov kev paub zoo thiab cov ntaub ntawv rau kev txhim kho tom ntej ntawm myostatin inhibitors.
Peb lub tuam txhab koom ua ke R & D, synthesis, ntau lawm, thiab xa tawm. Kev vam khom siab heev- thev naus laus zis thev naus laus zis, peb siv cov txheej txheem tsim khoom nruj GMP huv thiab kev tswj xyuas zoo thoob plaws tag nrho cov txheej txheem, tshwj xeeb hauv siab -purity peptide raw khoom. Peb cov khoom muaj kev paub zoo, nrog kev ruaj khov purity thiab kev ua haujlwm zoo, txhawb nqa ob qho tib si khoom siv thiab kho R & D. Peb tau cog lus los tsim lub zog peptide nrog thev naus laus zis thiab tswj kom zoo nrog kev ua haujlwm zoo. Nrog rau cov saw hlau thoob ntiaj teb paub tab, peb siv zog los tsim kom muaj -kev ua tau zoo, tus nqi- cov saw peptide zoo, ua haujlwm ua ke kom ua tiav kev sib koom ua lag luam hauv ntiaj teb kev noj qab haus huv.
Cim npe nrov: Siab{{0} zoo peptide tshuaj ACE-031 1mg/vial, Tuam Tshoj High-zoo peptide tshuaj ACE-031 1mg/vial manufacturers, lwm tus neeg, Hoobkas
